A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients with Essential Hypertension

Kyowa Kirin Co., Ltd.0 个研究点目标入组 144 人开始时间: 2025年4月17日最近更新: 2025年5月1日

试验速览

暂无简介。

•Voluntary consent to participate in this study must be given (in writing)
•Japanese or non-Asian healthy men 18 to < 55 years at the time of informed consent (Japanese healthy men 65 to < 80 years for the elderly cohort)
•BMI is within the specified range at screening
•Voluntary consent to participate in this study must be given (in writing)
•Japanese patients with essential hypertension, aged 18 to <65 years at the time of informed consent
•BMI is within the specified range at screening

•History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator.
•History of or current drug allergy
•History of or current alcoholism or drug addiction
•Smoking within the specified period
•infection within the specified period
•Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study
•History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator.
•History or of current drug allergy
•History of or current alcoholism or drug addiction
•Pregnant or breastfeeding patients, or patients willing to have a child during the study
•Smoking within the specified period
•infection within the specified period
•Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study

Number of participants with adverse events

未报告次要终点

发起方